Chimeric synthetic peptides as antigens for detection of antibodies to HIV-1 and HIV-2. 1996

K Shah, and C Davis, and J Wilson, and B Parekh
Department of Biological Sciences, Clark Atlanta University, Atlanta, Georgia 30314, USA.

Two chimeric peptides incorporating immunodominant sequences from both HIV-1 (LGIWGCSGKLICTT) and HIV-2 (LNSWGCAFRQVCHT) were synthesized. Peptides KS1-KS2 and KS2-KS1 represented sequences from the two viruses in both possible orders, separated by two glycine residues as spacers. These peptides were evaluated as antigens in an ELISA using a panel of specimens derived from HIV-1 (n = 25) and HIV-2 (n = 25) infected individuals and seronegative people (n = 38). The results were compared to plates coated with individual peptides KS1 and KS2 and to plates coated with two peptides (KS1 and KS2) together. Data demonstrated that individually, KS1 and KS2, are good antigens and can detect antibodies to their respective viruses quite efficiently. However, when coated together, their ability to detect antibodies to both HIV-1 and HIV-2 was reduced, as evidenced by a decrease in OD values obtained. The chimeric peptides KS1-KS2 and KS2-KS1 detected antibodies to HIV-1 and HIV-2; however, their sensitivity of detection was variable and dependent upon the order of their sequence. For both peptides, antibodies directed to the C-terminal portion were detected with higher sensitivity than those directed to the N-terminal part of the peptides. This may be related to peptide adsorption to the solid surface and epitope accessibility to the antibodies. Such chimeric antigens may be very useful for simultaneous detection of antibodies to HIV-1 and HIV-2.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015488 HIV Antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens. AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV
D015492 AIDS Serodiagnosis Immunologic tests for identification of HIV (HTLV-III/LAV) antibodies. They include assays for HIV SEROPOSITIVITY and HIV SERONEGATIVITY that have been developed for screening persons carrying the viral antibody from patients with overt symptoms of AIDS or AIDS-RELATED COMPLEX. AIDS Serology,HIV Serodiagnosis,HTLV-III Serodiagnosis,HTLV-III Serology,Serodiagnosis, AIDS,Serodiagnosis, HIV,Serodiagnosis, HTLV-III,Serology, AIDS,Serology, HTLV-III,AIDS Serodiagnoses,HIV Serodiagnoses,HTLV III Serodiagnosis,HTLV III Serology,HTLV-III Serodiagnoses,Serodiagnoses, AIDS,Serodiagnoses, HIV,Serodiagnoses, HTLV-III,Serodiagnosis, HTLV III,Serology, HTLV III
D016056 Immunodominant Epitopes Subunits of the antigenic determinant that are most easily recognized by the immune system and thus most influence the specificity of the induced antibody. Antigenic Determinants, Immunodominant,Antigens, Immunodominant,Epitopes, Immunodominant,Immunodominant Determinant,Immunodominant Domain,Immunodominant Epitope,Immunodominant Region,Immunodominant Site,Immunodominant Determinants,Immunodominant Domains,Immunodominant Regions,Immunodominant Sites,Determinant, Immunodominant,Determinants, Immunodominant,Determinants, Immunodominant Antigenic,Domain, Immunodominant,Domains, Immunodominant,Epitope, Immunodominant,Immunodominant Antigenic Determinants,Immunodominant Antigens,Region, Immunodominant,Regions, Immunodominant,Site, Immunodominant,Sites, Immunodominant

Related Publications

K Shah, and C Davis, and J Wilson, and B Parekh
January 2006, Biochemical and biophysical research communications,
K Shah, and C Davis, and J Wilson, and B Parekh
January 2007, Journal of immunological methods,
K Shah, and C Davis, and J Wilson, and B Parekh
January 1996, Archives of virology,
K Shah, and C Davis, and J Wilson, and B Parekh
May 2001, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
K Shah, and C Davis, and J Wilson, and B Parekh
September 1993, Nihon rinsho. Japanese journal of clinical medicine,
K Shah, and C Davis, and J Wilson, and B Parekh
January 1991, Journal of acquired immune deficiency syndromes,
K Shah, and C Davis, and J Wilson, and B Parekh
January 1998, Voprosy virusologii,
K Shah, and C Davis, and J Wilson, and B Parekh
January 1986, Ciba Foundation symposium,
K Shah, and C Davis, and J Wilson, and B Parekh
November 2013, Bioorganic & medicinal chemistry,
K Shah, and C Davis, and J Wilson, and B Parekh
January 1991, Viral immunology,
Copied contents to your clipboard!